The UK and US have hammered out a key commercial pact that will maintain no duties on UK pharmaceutical products going into the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to raise funding on drugs through the National Health Service (NHS). This move ensures that import taxes on these crucial exports will remain at zero for a timeframe of three years.
This development comes after earlier statements to dramatically increase tariffs on patented drug products, with figures discussed reaching one hundred percent.
"This agreement between the Britain strengthens the international landscape for new treatments and establishes long-overdue equity to American-British pharmaceutical trade," a release noted.
Trade Importance
Drugs are one of the UK's largest exports to the United States, which is clearly the largest market for leading British pharmaceutical firms.
Trade data show that in the 12 months leading up to September, the UK shipped medicines worth £11.1bn to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This deal protects jobs, stimulates funding and paves the way for the UK to establish itself as a international leader for life sciences," a minister stated.
Specific UK Commitments
The agreement involves several key pledges from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a target to raise total NHS spending on treatments from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, rebates were more than twenty percent.
Industry Background
This agreement takes place against a protracted row between the sector and the ministers over spending levels and NHS adoption.
The disagreement were heightened by assertions that American patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial expansions have been announced toward US facilities.
One official acknowledged that the NHS had to spend more on medicines, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
